Previous 10 | Next 10 |
– First-Ever Study to Have Evaluated the Safety and Efficacy of an Investigational RNAi Therapeutic in Infants and Children Under the Age of Six – – Lumasiran Demonstrated Clinically Significant Reduction in Urinary Oxalate Levels Relative to Baseline ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 4 th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 4:15 pm ET via webcast. A live a...
If you weren't paying attention during the last big stock market correction, don't worry. The next big dip is always right around the quarter. If you plan to buy up shares of the best the healthcare sector has to offer the next time the market panics, Teladoc Health (NYSE: TDOC) , Vee...
– Company Announces Potential for a Biannual Dosing Regimen Option for its Investigational RNAi Therapeutic Vutrisiran, Providing Support for Further Product Differentiation as a Potential Best-in-Class Agent – – New Clinical Data Presented at the European Society ...
BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...
Blackstone (NYSE: BX ) closes on the R&D funding part of the its previously announced $2B financing collaboration with Alnylam Pharmaceuticals (NASDAQ: ALNY ) to advance RNAi therapeutics for cardiovascular disease. More news on: The Blackstone Group Inc., Alnylam Pharmaceuticals...
Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously announced $2 billion strategic financing collaboration to accelerate the advancem...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Image source: The Motley Fool. Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Q2 2020 Earnings Call Aug 7, 2020 , 8:30 p.m. ET Operator Continue reading
Look at the comments on past Alnylam ( ALNY ) articles, and you'll see a vocal cadre of readers who have an otherwise admirable commitment to the notion that Alnylam is going to stumble at some point and not get up … and yet, the company keeps on executing past those worries. While th...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...